Saponin TQL1055 adjuvant-containing vaccine confers protection upon Mycobacterium tuberculosis challenge in mice

References

• WHO. Global tuberculosis report. 2022.
   Google Scholar
• Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet. 1995;346(8986):1339–10. doi:10.1016/S0140-6736(95)92348-9.
   PubMed Web of Science ®Google Scholar
• Lienhardt C, Fruth U, Greco M. The blueprint for vaccine research & development: walking the path for better TB vaccines. Tuberculosis (Edinb). 2012;92(Suppl 1):S33–5. doi:10.1016/S1472-9792(12)70011-2.
   PubMedGoogle Scholar
• Rook GA, Dheda K, Zumla A. Immune responses to tuberculosis in developing countries: implications for new vaccines. Nat Rev Immunol. 2005;5(8):661–7. doi:10.1038/nri1666.
   PubMed Web of Science ®Google Scholar
• Hawkridge T, Scriba TJ, Gelderbloem S, Smit E, Tameris M, Moyo S, Lang T, Veldsman A, Hatherill M, Merwe L, et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis. 2008;198(4):544–52. doi:10.1086/590185.
   PubMed Web of Science ®Google Scholar
• Tameris M, Geldenhuys H, Luabeya AK, Smit E, Hughes JE, Vermaak S, Hanekom WA, Hatherill M, Mahomed H, McShane H, et al. The candidate TB vaccine, MVA85A, induces highly durable Th1 responses. PLoS One. 2014;9(2):e87340. doi:10.1371/journal.pone.0087340.
   PubMed Web of Science ®Google Scholar
• Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekom WA, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. 2013;381(9871):1021–8. doi:10.1016/S0140-6736(13)60177-4.
   PubMed Web of Science ®Google Scholar
• Ndiaye BP, Thienemann F, Ota M, Landry BS, Camara M, Dieye S, Dieye TN, Esmail H, Goliath R, Huygen K, et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2015;3(3):190–200. doi:10.1016/S2213-2600(15)00037-5.
   PubMed Web of Science ®Google Scholar
• Tait DR, Hatherill M, Van Der Meeren O, Ginsberg AM, Van Brakel E, Salaun B, Scriba TJ, Akite EJ, Ayles HM, Bollaerts A, et al. Final analysis of a trial of M72/AS01 E vaccine to prevent tuberculosis. N Engl J Med. 2019;381(25):2429–39. doi:10.1056/NEJMoa1909953.
   PubMed Web of Science ®Google Scholar
• Van Der Meeren O, Hatherill M, Nduba V, Wilkinson RJ, Muyoyeta M, Van Brakel E, Ayles HM, Henostroza G, Thienemann F, Scriba TJ, et al. Phase 2b controlled trial of M72/AS01 E vaccine to prevent tuberculosis. N Engl J Med. 2018;379(17):1621–34. doi:10.1056/NEJMoa1803484.
   PubMed Web of Science ®Google Scholar
• Gopal R, Rangel-Moreno J, Fallert Junecko BA, Mallon DJ, Chen K, Pociask DA, Connell TD, Reinhart TA, Alcorn JF, Ross TM, et al. Mucosal pre-exposure to Th17-inducing adjuvants exacerbates pathology after influenza infection. Am J Pathol. 2014;184(1):55–63. doi:10.1016/j.ajpath.2013.09.012.
   PubMed Web of Science ®Google Scholar
• Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, Cilley GE, Shen F, Eaton SM, Gaffen SL, Swain SL, et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during mycobacterium tuberculosis challenge. Nat Immunol. 2007;8(4):369–77. doi:10.1038/ni1449.
   PubMed Web of Science ®Google Scholar
• Slight SR, Rangel-Moreno J, Gopal R, Lin Y, Fallert Junecko BA, Mehra S, Selman M, Becerril-Villanueva E, Baquera-Heredia J, Pavon L, et al. CXCR5+ T helper cells mediate protective immunity against tuberculosis. J Clin Invest. 2013;123:712–26. doi:10.1172/JCI65728.
   PubMed Web of Science ®Google Scholar
• Lu LL, Chung AW, Rosebrock TR, Ghebremichael M, Yu WH, Grace PS, Schoen MK, Tafesse F, Martin C, Leung V, et al. A functional role for antibodies in tuberculosis. Cell. 2016;167(2):433–43.e14. doi:10.1016/j.cell.2016.08.072.
   PubMed Web of Science ®Google Scholar
• Dijkman K, Sombroek CC, Vervenne RAW, Hofman SO, Boot C, Remarque EJ, Kocken CHM, Ottenhoff THM, Kondova I, Khayum MA, et al. Prevention of tuberculosis infection and disease by local BCG in repeatedly exposed rhesus macaques. Nat Med. 2019;25(2):255–62. doi:10.1038/s41591-018-0319-9.
   PubMed Web of Science ®Google Scholar
• Lecrenier N, Beukelaers P, Colindres R, Curran D, De Kesel C, De Saegher J-P, Didierlaurent AM, Ledent EY, Mols JF, Mrkvan T, et al. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention. Expert Rev Vaccines. 2018;17(7):619–34. doi:10.1080/14760584.2018.1495565.
   PubMed Web of Science ®Google Scholar
• Skeiky YA, Alderson MR, Ovendale PJ, Guderian JA, Brandt L, Dillon DC, Campos-Neto A, Lobet Y, Dalemans W, Orme IM, et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol. 2004;172(12):7618–28. doi:10.4049/jimmunol.172.12.7618.
   PubMed Web of Science ®Google Scholar
• Wang P. Natural and synthetic saponins as vaccine adjuvants. Vaccines. 2021;9(3):222. doi:10.3390/vaccines9030222.
   Web of Science ®Google Scholar
• Laurens MB. RTS,S/AS01 vaccine (Mosquirix™): an overview. Hum Vaccin Immunother. 2020;16(3):480–9. doi:10.1080/21645515.2019.1669415.
   PubMed Web of Science ®Google Scholar
• Bennett SR, Martin T. 1045. Safety of the synthetic saponin adjuvant TQL1055: preliminary results from a first-in-humans trial. Open Forum Infect Dis. 2021;8(Supplement_1):S614–S. doi:10.1093/ofid/ofab466.1239.
   Google Scholar
• Buzz C, Farris E, Bennett SR, Frenchick P, Martin T. 1237. Robust adjuvant activity and dose-sparing potential of the novel semisynthetic saponin adjuvant TQL1055 for seasonal and pandemic influenza. Open Forum Infect Dis. 2020;7(Supplement_1):637–8. doi:10.1093/ofid/ofaa439.1422.
   Google Scholar
• Hernandez A, Zhou J, Bohannon JK, McBride MA, Gibson-Corley KN, Patil NK, Owen AM, Burelbach KR, Sherwood ER. Intrapulmonary treatment with a novel tlr4 agonist confers protection against Klebsiella Pneumonia. Shock (Augusta, Ga). 2022;58(4):295–303. doi:10.1097/SHK.0000000000001977.
   PubMed Web of Science ®Google Scholar
• Chandrasekar SS, Kingstad-Bakke BA, Wu CW, Phanse Y, Osorio JE, Talaat AM. A DNA prime and MVA boost strategy provides a robust immunity against infectious bronchitis virus in chickens. Vaccines. 2023;11(2):11. doi:10.3390/vaccines11020302.
   Web of Science ®Google Scholar
• Ahmed M, Smith DM, Hamouda T, Rangel-Moreno J, Fattom A, Khader SA. A novel nanoemulsion vaccine induces mucosal interleukin-17 responses and confers protection upon mycobacterium tuberculosis challenge in mice. Vaccine. 2017;35(37):4983–9. doi:10.1016/j.vaccine.2017.07.073.
   PubMed Web of Science ®Google Scholar
• Ahmed M, Jiao H, Domingo-Gonzalez R, Das S, Griffiths KL, Rangel-Moreno J, Nagarajan UM, Khader SA. Rationalized design of a mucosal vaccine protects against Mycobacterium tuberculosis challenge in mice. J Leukoc Biol. 2017;101(6):1373–81. doi:10.1189/jlb.4A0616-270R.
   PubMed Web of Science ®Google Scholar
• Gopal R, Lin Y, Obermajer N, Slight S, Nuthalapati N, Ahmed M, Kalinski P, Khader SA. IL-23-dependent IL-17 drives Th1-cell responses following mycobacterium bovis BCG vaccination. Eur J Immunol. 2012;42(2):364–73. doi:10.1002/eji.201141569.
   PubMed Web of Science ®Google Scholar
• Swanson RV, Gupta A, Foreman TW, Lu L, Choreno-Parra JA, Mbandi SK, Rosa BA, Akter S, Das S, Ahmed M, et al. Antigen-specific B cells direct T follicular-like helper cells into lymphoid follicles to mediate mycobacterium tuberculosis control. Nat Immunol. 2023;24(5):855–68. doi:10.1038/s41590-023-01476-3.
   PubMed Web of Science ®Google Scholar
• Mustafa AS. Immunological characterization of proteins expressed by genes located in Mycobacterium tuberculosis-specific genomic regions encoding the ESAT6-like proteins. Vaccines. 2021;9(1):27. doi:10.3390/vaccines9010027.
   Web of Science ®Google Scholar
• Prendergast KA, Counoupas C, Leotta L, Eto C, Bitter W, Winter N, Triccas JA. The Ag85B protein of the BCG vaccine facilitates macrophage uptake but is dispensable for protection against aerosol Mycobacterium tuberculosis infection. Vaccine. 2016;34(23):2608–15. doi:10.1016/j.vaccine.2016.03.089.
   PubMed Web of Science ®Google Scholar
• Ahlberg V, Hjertner B, Wallgren P, Hellman S, Lövgren Bengtsson K, Fossum C. Innate immune responses induced by the saponin adjuvant matrix-M in specific pathogen free pigs. Vet Res. 2017;48(1):30. doi:10.1186/s13567-017-0437-2.
   PubMedGoogle Scholar
• Griffiths KL, Ahmed M, Das S, Gopal R, Horne W, Connell TD, Moynihan KD, Kolls JK, Irvine DJ, Artyomov MN, et al. Targeting dendritic cells to accelerate T-cell activation overcomes a bottleneck in tuberculosis vaccine efficacy. Nat Commun. 2016;7(1):13894. doi:10.1038/ncomms13894.
   PubMedGoogle Scholar
• Das S, Marin ND, Esaulova E, Ahmed M, Swain A, Rosa BA, Mitreva M, Rangel-Moreno J, Netea MG, Barreiro LB, et al. Lung epithelial signaling mediates early vaccine-induced CD4 + T cell activation and mycobacterium tuberculosis control. mBio. 2021;12(4):e0146821. doi:10.1128/mBio.01468-21.
   PubMed Web of Science ®Google Scholar
• Khader SA, Divangahi M, Hanekom W, Hill PC, Maeurer M, Makar KW, Mayer-Barber KD, Mhlanga MM, Nemes E, Schlesinger LS, et al. Targeting innate immunity for tuberculosis vaccination. J Clin Invest. 2019;129(9):3482–91. doi:10.1172/JCI128877.
   PubMed Web of Science ®Google Scholar
• Nemes E, Khader SA, Swanson RV, Hanekom WA. Targeting unconventional host components for vaccination-induced protection against TB. Front Immunol. 2020;11:1452. doi:10.3389/fimmu.2020.01452.
   PubMed Web of Science ®Google Scholar
• Marty-Roix R, Vladimer GI, Pouliot K, Weng D, Buglione-Corbett R, West K, MacMicking JD, Chee JD, Wang S, Lu S, et al. Identification of QS-21 as an inflammasome-activating molecular component of saponin adjuvants. J Biol Chem. 2016;291(3):1123–36. doi:10.1074/jbc.M115.683011.
   PubMed Web of Science ®Google Scholar